Scarica l'app Stockscreener
0.307
4.06%
-0.013
Dopo l'orario di chiusura:
.30
-0.007
-2.28%
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - The Globe and Mail
Why Is Intensity Therapeutics Stock (INTS) Down 50% Today? - The Globe and Mail
Intensity Therapeutics Completes $1.9 Million Stock Offering - TipRanks
Intensity Therapeutics Stock Falls 44% Today Should You Buy the Dip or Stay Away - thekhabrilal
Intensify Therapeutics slumps 27%, prices $2M stock offering - MSN
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - mx.advfn.com
Intensity Therapeutics (INTS) Shares Dive 27% Following Public O - GuruFocus
Intensity Therapeutics shares plummet on proposed public offering - MSN
ThinkEquity Leads Offering for INTS | INTS Stock News - GuruFocus
Intensity Therapeutics Prices Public Offering Of 6,675,000 Shares At $0.30 Per Share - MarketScreener
Intensity Therapeutics, Inc. Announces Pricing of Public Offering - The Victoria Advocate
INTS: Intensity Therapeutics Reports Promising Results from Phas - GuruFocus
Intensity Therapeutics announces public offering of common stock By Investing.com - Investing.com India
Intensity Therapeutics (INTS) Announces Public Offering to Support Clinical Studies | INTS Stock News - GuruFocus
Intensity Therapeutics announces common stock offering, no amount given - TipRanks
Intensity Therapeutics announces public offering of common stock - Investing.com
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - StreetInsider
SEC Form 424B5 filed by Intensity Therapeutics Inc. - Quantisnow
Intensity Therapeutics Inc (INTS) Stock: A Year of Stock Market Dynamics - investchronicle.com
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCI - StreetInsider
Korn Ferry Sets Fiscal Year-End Earnings Release Date: Key Q4 Results Coming June 18 - Stock Titan
Intensity’s cancer drug shows tumor necrosis in early-stage study By Investing.com - Investing.com Nigeria
DXC Achieves Clean Sweep in NelsonHall's 2025 AI Infrastructure Management Rankings - Stock Titan
Intensity Therapeutics reports data from Invincible-4 study - TipRanks
Shelton-based biotech faces delisting threat from Nasdaq - Hartford Business Journal
Intensity Therapeutics Faces Nasdaq Delisting Notice - TipRanks
ibex to Showcase Industry’s Best AI-Powered CX Solutions at CCW Customer Contact Week 2025 - Stock Titan
New Cancer Drug Triples Survival Time for Hard-to-Treat Lung Cancer Patients in Phase 2 Trial - Stock Titan
Magnite Revolutionizes CTV Advertising with Exclusive AI Technology for Scene-by-Scene Ad Targeting - Stock Titan
Full Stock Market News from 2025-06-05 - Stock Titan
Cognizant Achieves 80% Migration Automation as Snowflake Names it Top Global Implementation Partner - Stock Titan
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan
AECOM Sets July Payment Date for $0.26 Quarterly DividendKey Dates Inside - Stock Titan
IonQ Expands Quantum Computing Empire: 20+ Patents Added in Strategic Lightsynq Acquisition - Stock Titan
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - The Globe and Mail
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Harte Hanks Acquires Exclusive Rights to License ADS Data Direct's Premier Medical Ailment Database - Stock Titan
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - GuruFocus
Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - Morningstar
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Clean Tech Breakthrough: Zentek Partners With RSK to Launch Advanced Air Filters Across 20+ Global Markets - Stock Titan
Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga
Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com
Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus
Assembly's New META-Backed Marketing Tool Cuts Modeling Time 26%, Boosts ROI 13% With AI Innovation - Stock Titan
Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com
Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India
Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma - openPR.com
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
0.78%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):